AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30169915
Drug: OIT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OIT with pasteurized egg white (PEW), target dose 3.3 g PEW proteins, buildup pattern PII (30% weekly increments)
Trial: 29619533
Drug: CBD (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD (600 mg/day)
Trial: 26706022
Drug: Probiotic supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplements (n = 20)
Trial: 17509869
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia (group EA) with a 7‐mL epidural bolus 0.1% bupivacaine containing fentanyl 50 mug (n=20)
Trial: 16450805
Drug: Techniques or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Techniques or adjuvant medical treatment to reduce clot expansion and rebleeding
Trial: 9700469
Drug: Triglyceride emulsion
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglyceride emulsion infusion (Lipid infusion study)
Trial: 9700469
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (Saline infusion study)
Trial: 7623616
Drug: CI-979 (0.5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-979 (0.5-mg q6h, 1-mg q12h, 1-mg q6h, 2-mg q12h, 2-mg q6h, 2.5-mg q6h, and 3-mg q6h)
Trial: 2569324
Drug: Conventional (C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional (C) propranolol 160 mg
Trial: 2569324
Drug: Long acting
RxNorm normalized name: Long Acting Nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long acting (LA) propranolol 160 mg
Trial: 7176839
Drug: Prednisone treatment
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone treatment in patients with CAH (total group)
Trial: 7176839
Drug: Prednisone treatment
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone treatment in patients with cirrhosis and CAH (Group I A)
Trial: 7176839
Drug: Prednisone treatment
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone treatment in patients with probably cirrhosis and CAH (Group I B)
Trial: 7176839
Drug: Prednisone treatment
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone treatment in patients compatible with but not diagnostic for cirrhosis and CAH (Group I C)
Trial: 7176839
Drug: Prednisone treatment
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone treatment in patients without CAH (Group II A + B + C)
Trial: 26303188
Drug: Fentanyl buccal
RxNorm normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal tablets (FBTs)
Trial: 17308893
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg daily with oral etoposide starting at 50 mg every other day
Trial: 17308893
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide alone (baseline pharmacokinetic studies)
Trial: 17308893
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg daily with oral etoposide
Trial: 12877651
Drug: Dietary supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplementation with arachidonic acid (AA) at a dosage of 4 g/day for 8 weeks
Trial: 11161542
Drug: GLY-GLN (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLY-GLN (500 ml glycyl-glutamine; 35 g GLN; 0.5 g/kg BW)
Trial: 11161542
Drug: Control (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (1500 ml Vamin)
Trial: 11161542
Drug: ALA-GLN (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA-GLN (500 ml alanyl-glutamine; 35 g GLN; 0.5 g/kg BW)
Trial: 9587049
Drug: Clovir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clovir (400 mg)
Trial: 9587049
Drug: Zovirax (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zovirax (400 mg)
Trial: 4629183
Drug: D.S.C.G.-isoprenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D.S.C.G.-isoprenaline
Trial: 4629183
Drug: D.S.C.G.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D.S.C.G.
Trial: 4629183
Drug: D.S.C.G.-isoprenaline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D.S.C.G.-isoprenaline and D.S.C.G.
Trial: 4629183
Drug: Full dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dosage
Trial: 31821109
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy plus trastuzumab (CRxT)
Trial: 31821109
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy alone (CRx)
Trial: 25807902
Drug: Full-mouth therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-mouth therapy (complete scaling and root planing in one stage within 24 h)
Trial: 25807902
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (scaling and root planing performed by quadrant over a period of 4 weeks)
Trial: 19697106
Drug: Oral dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosage form of tolterodine tartrate
Trial: 14760340
Drug: Urapidil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil (200 microg/kg intravenously, followed by 30 mg/d orally)
Trial: 17402274
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg once daily
Trial: 1997054
Drug: Temazepam 30
RxNorm normalized name: temazepam 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam 30 mg in elixir formulation
Trial: 1997054
Drug: Temazepam 30
RxNorm normalized name: temazepam 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam 30 mg in capsule formulation
Trial: 6519348
Drug: Nimesulide 200
RxNorm normalized name: nimesulide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide 200 mg b.i.d.
Trial: 29752593
Drug: Kallidinogenase (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kallidinogenase (150 units administered daily for 52 weeks)
Trial: 20823433
Drug: Fluorouracil plus
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil plus folinic acid (20 mg/m² intravenous bolus injection followed by 425 mg/m² intravenous bolus injection given 1-5 days every 28 days)
Trial: 20823433
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg/m² intravenous infusion once a week for 3 of every 4 weeks)
Trial: 18166759
Drug: Epinephrine ampules
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine ampules labeled with mass concentration (1 mg in 1 mL)
Trial: 18166759
Drug: Epinephrine ampules
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine ampules labeled with ratio (1 mL of a 1:1000 solution)
Trial: 11154807
Drug: Single-day praziquantel
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-day praziquantel therapy (n=14)
Trial: 11154807
Drug: Non-treatment (n=12)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment (n=12)
Trial: 11154807
Drug: Praziquantel treatment
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel treatment after non-treatment
Trial: 1829091
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of long and short acting GnRH analogues (group II)
Trial: 6673029
Drug: Pentoxifylline (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (1,200 mg/day for 30 days)
Trial: 31237645
Drug: P2Y12 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P2Y12 inhibitor monotherapy after 3 months of DAPT (n=1495)
Trial: 31237645
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) for 12 months (n=1498)
Trial: 27667369
Drug: NAVIGATE treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAVIGATE treatment (comprehensive, team-based treatment program with ≥5h of SEE services per week)
Trial: 25097397
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of beta urogastrone (recombinant human epidermal growth factor) gel
Trial: 23210239
Drug: Rebamipide tablets
RxNorm normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Rebamipide tablets from Yuanlijian (test)
Trial: 23210239
Drug: Rebamipide tablets
RxNorm normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Rebamipide tablets from Otsuka (reference)
Trial: 15868146
Drug: Trastuzumab (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly for up to 840 days)
Trial: 17661792
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin re-uptake inhibitor (SSRI) treatment
Trial: 30272528
Drug: 150 μg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 μg/day iodine
Trial: 30272528
Drug: 300 μg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 μg/day iodine
Trial: 25733331
Drug: Large doses
RxNorm normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large doses of ambroxol hydrochloride
Trial: 25733331
Drug: Normal doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal doses of ambroxol hydrochloride
Trial: 17032185
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (fentanyl plus propofol, midazolam plus propofol, fentanyl plus midazolam plus propofol)
Trial: 10669283
Drug: Oral ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketamine 6.0 mg/kg
Trial: 10669283
Drug: Rectal diazepam
RxNorm normalized name: diazepam Rectal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diazepam 0.5 mg/kg and diclofenac 12.5 mg
Trial: 3177831
Drug: Midazolam (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.15 mg/kg) combined with Piritramid (0.1 mg/kg)
Trial: 3177831
Drug: Thalamonal (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalamonal (0.04 ml/kg)
Trial: 30676232
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care and daily activities (Control group).
Trial: 29031658
Drug: Brimonidine 0.33%
RxNorm normalized name: Brimonidine 0.33% Topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine 0.33% topical gel
Trial: 21166575
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy targeting normal glycosylated hemoglobin (HbA1c) levels, tight lipid control with fenofibrate and statin, aggressive blood pressure treatment with a systolic blood pressure goal of 120 mmHg
Trial: 8737633
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 400 mg of buflomedil during 4 h of dialysis
Trial: 8737633
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of buflomedil in six other patients maintained on intermittent hemodialysis (3 per week) for 4 weeks
Trial: 31851170
Drug: 2% articaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% articaine solution
Trial: 10619812
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine solution
Trial: 24525598
Drug: Icodextrin-based dialysis
RxNorm normalized name: Icodextrin Peritoneal Dialysis Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icodextrin-based dialysis solution (ICO group)
Trial: 22889955
Drug: Raloxifene hydrochloride
RxNorm normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene hydrochloride (RLX) (60 mg/day) plus SOC (PegIFNα2a 180 μg/week and RBV 600‐1,000 mg/day)
Trial: 22889955
Drug: SOC only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC only (PegIFNα2a 180 μg/week and RBV 600‐1,000 mg/day)
Trial: 20233275
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg vardenafil ODT on demand
Trial: 16100448
Drug: Inhaled glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocorticoids (fluticasone propionate 1,000 microgram/day) for 4 weeks
Trial: 10084469
Drug: Salmeterol powder
RxNorm normalized name: salmeterol Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol powder (50 microg) twice daily for 52 weeks
Trial: 2202792
Drug: 10 U/mL
RxNorm normalized name: HEPARIN 10 U/ML PF LOCK FLUSH SYR 5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 U/mL heparin (H)
Trial: 2202792
Drug: 10 U/mL
RxNorm normalized name: HEPARIN 10 U/ML PF LOCK FLUSH SYR 5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 U/mL heparin and 25 micrograms/mL vancomycin (H-V)
Trial: 31201957
Drug: Krill oil
RxNorm normalized name: Krill oil
DrugBank: Krill oil (DB16615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krill oil (KO) supplementation (5 g)
Trial: 31201957
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation (5 g)
Trial: 25869324
Drug: High-dose ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ibuprofen (HDI)
Trial: 15284085
Drug: Oral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estrogen (0.625 mg per day)
Trial: 15284085
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (100 microg per day)
Trial: 8214918
Drug: 8% CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% CO2 inhalation
Trial: 8214918
Drug: 2, 4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2, 4, 6% CO2 inhalation
Trial: 31826183
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg of caffeine (CAF)
Trial: 31826183
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg of cellulose as a placebo (PLA)
Trial: 29791677
Drug: Monthly medical
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly medical visits with provision of insulin pens and strips for blood glucose measurement, including insulin pen, refills of Neutral Protamine Hagedorn and regular insulin, needles for the pen, blood glucose meter, and capillary blood glucose tests (three tests/day) for six months.
Trial: 22333849
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (4 doses of 20 mg at 1-month intervals)
Trial: 22333849
Drug: Nontreatment (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nontreatment (no medicine)
Trial: 20102447
Drug: 4-mg silodosin
RxNorm normalized name: silodosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mg silodosin
Trial: 18336918
Drug: CGT (Complicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGT (Complicated Grief Therapy)
Trial: 15901743
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg IM ziprasidone
Trial: 15901743
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg IM ziprasidone
Trial: 15901743
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg IM ziprasidone
Trial: 15901743
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg IV ziprasidone
Trial: 15901743
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral ziprasidone
Trial: 10637713
Drug: roxatidine 75
RxNorm normalized name: roxatidine 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxatidine 75 mg hs for 8 weeks
Trial: 10637713
Drug: roxatidine 75
RxNorm normalized name: roxatidine 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxatidine 75 mg hs for 8 weeks + metronidazole 250 mg and amoxicillin 250 mg qid for 1 week on the 3rd week
Trial: 10637713
Drug: Mylanta (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mylanta (20 ml qid for 8 weeks)
Trial: 10637713
Drug: Mylanta (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mylanta (20 ml qid for 8 weeks) + metronidazole 250 mg and amoxicillin 250 mg qid for 1 week on the 3rd week
Trial: 1822427
Drug: Day center
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day center treatment
Trial: 1822427
Drug: Walk-in clinic
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walk-in clinic treatment
Trial: 25233911
Drug: Additive solution-7
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additive solution-7 (AS-7)
Trial: 25233911
Drug: Control solution
RxNorm normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solution AS-1
Trial: 22981094
Drug: Submucosal 2
RxNorm normalized name: mepivacaine
DrugBank: Mepivacaine (DB00961)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Submucosal 2 mL 100 mg tramadol injection (group T)
Trial: 22981094
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution (group P)
Trial: 22635164
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg testosterone undecanoate (intramuscular injection at weeks 0, 6, 18, 30, and 42)
Trial: 22635164
Drug: Placebo (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intramuscular injection at weeks 0, 6, 18, 30, and 42)
Trial: 19135839
Drug: Contrast-enhanced ultrasound
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced ultrasound imaging (CEUS) with a dose of 2.4 mL of a second-generation contrast agent.
Trial: 17690122
Drug: Prednisone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (30 mg.day(‐1))
Trial: 16212139
Drug: Risedronate at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate at 5 mg/d
Trial: 16212139
Drug: Risedronate at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate at 15 mg/d
Trial: 16212139
Drug: Risedronate at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate at 35 mg once weekly
Trial: 16212139
Drug: Risedronate at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate at 50 mg once weekly
Trial: 19093930
Drug: Medicare Part
RxNorm normalized name: benzocaine / menthol Medicated Pad [Medicaine Sting]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicare Part D coverage for clopidogrel, proton pump inhibitors (PPIs), warfarin, and statins
Trial: 19093930
Drug: Other study
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other study drug classes (warfarin, statins, benzodiazepines)
Trial: 10823442
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg orally 1 hour before barium suspension
Trial: 10823442
Drug: Metoclopramide 20
RxNorm normalized name: metoclopramide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 20 mg orally 1 hour before barium suspension
Trial: 8542002
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (100,000 IU oral)
Trial: 23510792
Drug: Rectal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal misoprostol (600 ?g)
Trial: 23510792
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion (20 intravenous units)
Trial: 15218330
Drug: benidipine (4-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benidipine (4-8 mg/day)
Trial: 15218330
Drug: nifedipine CR
RxNorm normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine CR (20-40 mg/day)